Information That Can Help Predict Chemotherapy Benefit
Oncotype DX is a test that examines a breast cancer patient’s tumor tissue at a molecular level, and gives information about her individual disease. This information can help tailor treatment for her breast cancer. Oncotype DX is the first and only gene expression test that has been accepted as demonstrating the ability to predict a patient’s benefit from chemotherapy as well as her risk of recurrence.
The Oncotype DX assay is intended to be used by women with early-stage (Stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy.
Oncotype DX has been included in the 2007 American Society of Clinical Oncology (ASCO) Clinical Guidelines on Use of Tumor Markers in Breast Cancer. This represents a significant step forward for the role of molecular diagnostics in breast cancer treatment planning.
Oncotype DX has also been included in the National Comprehensive Cancer Network (NCCN) 2008 Breast Cancer Treatment Guidelines. This inclusion reinforces the significance of molecular diagnostics in breast cancer treatment planning and, in particular, the potential value of the individualized information provided by Oncotype DX.
A recent study has shown that Oncotype DX may also be informative for post-menopausal women with node-positive, hormone receptor-positive (HR+) invasive breast cancer.
For complete information on Oncotype DX for Patients & Caregivers, Healthcare Providers, and Managed Care Organizations, visit OncotypeDX.com.
For additional information for Patients & Caregivers, visit MyTreatmentDecision.com.